Cambrex is a leading small molecule company that provides drug substance, drug product, and analytical services across the entire drug lifecycle. Cambrex Edinburgh is a world-class facility site on Edinburgh Technopole, within Midlothian Science Zone, providing solid form development services for drug substance and drug product.
Cambrex has a presence in thirteen locations globally, including a corporate headquarters in East Rutherford, NJ, USA. The company has now received CMO awards for seven consecutive years, and this year, has been recognised in the following categories: Capabilities (Overall, Small Pharma), Compatibility (Overall, Small Pharma), Expertise (Overall, Small Pharma), Quality (Overall, Small Pharma), Reliability (Small Pharma), and Service (Overall, Small Pharma).
“Once again, Cambrex is honored to be recognized by our customers and industry peers as a leading supplier to the pharmaceutical industry. Demand for small molecule manufacturing constantly grows and evolves, and we are committed to investing in the capacity, capabilities and expertise to further strengthen our position as a market-leading CDMO delivering customized, customer-centric solutions.”
Tom Loewald, Chief Executive Officer at Cambrex
“Congratulations to all the 2021 CMO Leadership Award winners; you keep the biopharma industry moving forward. An award in any category – capabilities, compatibility, expertise, quality, reliability and service – acknowledges your advanced leadership and effective execution and that rare flexibility to serve all customers through even the most difficult of times.”
Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma
In 2019, Cambrex was acquired by funds advised by Permira, a global investment firm, to continue to build upon Cambrex’s market leading position in API development and manufacturing and support the growth of its end-to-end integrated service offerings across the pharmaceutical value chain.
Established in 2011, the CMO Leadership Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing. The awards are presented by Outsourced Pharma, Life Science Leader magazine and Industry Standard Research.
In late 2020, Cambrex completed expansion of its solid form screening and crystallization process development facility at their Scottish HQ on Edinburgh Technopole. This major expansion project has seen the facility’s total footprint double to 15,000 square feet, with existing laboratory space having been refurbished, with an additional 3,500 square feet of laboratory space made available.